Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Larimar Therapeutics Inc. buy tamam

Larimar Therapeutics Inc.
Start price
€56.41
05.05.17 / 50%
Target price
€64.94
22.05.17
Performance (%)
-21.33%
End price
€44.38
22.05.17
Summary
This prediction ended on 22.05.17 with a price of €44.38. The prediction for Larimar Therapeutics Inc. disappointed with a performance of -21.33%. tamam has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Larimar Therapeutics Inc. 5.143% 5.143% -2.128% 5.747%
iShares Core DAX® -0,05 % 5,96 % 7,40 % 65,85 %
iShares Nasdaq 100 0,92 % 3,69 % 28,14 % 93,30 %
iShares Nikkei 225® 3,01 % 6,64 % 48,89 % 89,08 %
iShares S&P 500 -0,36 % 2,75 % 22,53 % 71,94 %

Comments by tamam for this prediction

In the thread Zafgen Inc. diskutieren
Prediction Buy
Perf. (%) -21.33%
Target price 5.412
Change
Ends at 22.05.17

Zafgen updates on obesity drug


Zafgen (NASDAQ:ZFGN) says MetAP2 inhibitor ZGN-1061 was well tolerated and safe in a Phase 1 trial on obesity. The trial indicated improvements in metabolic parameters for patients.


tamam 
0
Report Share
05.05.17
Prediction Buy
Perf. (%) -21.33%
Target price 5.412
Change
Ends at 22.05.17

(Vom Mitglied beendet)

tamam 
0
Report Share
22.05.17